Loading...

Home
ETF
CCCC

CCCC

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CCCC News

Replimune Receives FDA Support for BLA Resubmission

Jun 01 2026NASDAQ.COM

C4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results

May 29 2026seekingalpha

C4 Therapeutics Q1 Earnings Beat Expectations with Revenue of $6.15M

May 12 2026seekingalpha

C4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs

Apr 09 2026seekingalpha

C4 Therapeutics Expands Partnership with Roche for Cancer Treatments

Apr 09 2026stocktwits

C4 Therapeutics Partners with Roche for DAC Development

Apr 09 2026NASDAQ.COM

C4 Therapeutics Enhances Ongoing Partnership with Roche via New Collaboration to Explore and Develop Degrader-Antibody Conjugates (DACs)

Apr 09 2026moomoo

C4 Therapeutics Q4 Earnings Exceed Expectations

Feb 26 2026seekingalpha

C4 Therapeutics Stock Analysis and Outlook

Feb 20 2026Yahoo Finance

C4 Therapeutics Grants Stock Options to New Employee

Feb 09 2026Yahoo Finance

C4 Therapeutics to Initiate Two Cemsidomide Trials in 2026

Jan 14 2026Globenewswire

Most Active Stocks After Hours on December 18, 2025: BAC, C, NVDA, CCCC, GRAB, RXRX, AAPL, QQQ, COMP, PCG, PGRE, NU

Dec 18 2025NASDAQ.COM

Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades

Dec 02 2025Benzinga

Cloudflare Analyst Starts Coverage Optimistically; Check Out Tuesday's Top 5 Initiations

Dec 02 2025Benzinga

C4 Therapeutics Launches $400 Million Mixed Shelf Offering

Nov 21 2025SeekingAlpha

Precision Oncology Approaches Drive $312B Market Transformation

Oct 17 2025PRnewswire